Integrating Clinical, Protein Expression, and Genetic Markers to Predict Lymphedema in Breast Cancer
N/A
The goal of this observational ambidirectional cohort study is to develop a...
Status
Completed
Location
Dharmais Cancer Hospital
Start Date
2022-10-11
Trial ID
NCT07252843
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
PHASE1
The goal of this clinical research study is to find the recommended safe do...
Status
Recruiting
Location
The University of Texas M. D. Anderson Cancer Center
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
PHASE1
This is a phase 1 basket trial of TGFBR2 KO CAR27/IL-15 NK cells after lymp...
Status
Recruiting
Location
The University of Texas M. D. Anderson Cancer Center
Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)
PHASE1
To find the recommended dose of an investigational therapy called chimeric ...
Status
Recruiting
Location
The University of Texas M. D. Anderson Cancer Center
Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma
PHASE1
Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cel...
Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
PHASE1
The goal of this clinical research study is to study the recommended dose o...